FELDAN THERAPEUTICS RECOGNIZED AS A 2026 I.D.E.A.L. BIOSCIENCE EMPLOYER™ BY BIOTALENT CANADA

Quebec City, Canada – January 27, 2026 – Feldan Therapeutics (“Feldan”), a clinical-stage biotech company specializing in the development of therapies based on intracellular delivery, is proud to announce that it has been recognized by BioTalent Canada as a 2026 I.D.E.A.L. Bioscience Employer™.  

The I.D.E.A.L. Bioscience Employer™ Recognition Program recognizes organizations across Canada’s bio-economy that demonstrate leadership in inclusion, diversity, equity, and accessibility (IDEA) and translate these principles into tangible workplace practices. The distinction highlights employers that go beyond policy statements to create work environments where individuals can belong, contribute, and succeed, positioning Feldan among industry leaders in inclusive and innovative work environments. Recipients are selected based on rigorous evaluation across key criteria including alignment of IDEA principles with organizational strategy, leadership accountability, and inclusive talent management practices and efforts to create a culture of belonging.  

“Recognition as an I.D.E.A.L. Bioscience Employer is a differentiator in today’s market,” says Rob Henderson, President and CEO of BioTalent Canada. “It tells job seekers, partners and investors that your organization is committed to excellence, not just in science, but in the way you support and develop your people. Diversity and inclusion is not a charitable endeavour – every study out there indicates it’s a smart way of building your company.” 

“At Feldan, we believe innovation thrives when everyone feels they belong. This recognition reflects our dedication to celebrating unique strengths, fostering opportunities for all, and embedding IDEA principles into our vision, strategies, and outcomes. It belongs to every member of our team, whose daily interactions and initiatives bring our culture and values to life. We are honored to be among the leaders shaping a more inclusive future for our industry.” 

Feldan remains committed to advancing inclusive practices that support its mission of developing innovative therapies for patients, in a workplace where all individuals’ contributions are valued and drive meaningful impact. 

About Feldan
Feldan is a clinical-stage biotech company that specializes in the development of treatments based on the intracellular delivery of therapeutics. Feldan has developed the Feldan Shuttle, a proprietary peptide-based technology that enables safe, rapid, and efficient local delivery of antisense oligonucleotides (ASO) to cells. This technology unlocks the potential for a new generation of therapeutics by giving access to intracellular targets that are otherwise beyond reach.  

Feldan’s pipeline focuses on diseases affecting the skin and lungs. The company is conducting a Phase 1/2a clinical trial of FLD-103, a non-surgical treatment for basal cell carcinoma (BCC). To offer additional life-changing therapeutics to patients, Feldan is advancing FLD-201, an inhaled therapy for mucus-driven diseases such as non-cystic fibrosis bronchiectasis (NCFB) and chronic bronchitis, currently in preclinical development, while further developing its Shuttle technology for broader therapeutic applications. 

For more information: www.feldan.com 

About BioTalent Canada
BioTalent Canada supports the people behind life-changing science. Trusted as the go-to source for labour market intelligence, BioTalent Canada guides bio-economy contributors with evidence-based data and industry-driven standards. BioTalent Canada, as a workforce development council, is focused on igniting the industry’s brainpower, bridging the gap between job-ready talent and employers, and ensuring the long-term agility, resiliency, and sustainability of one of Canada’s most vital sectors.    

BioTalent Canada has received varied distinctions following a thorough and independent analysis of the organization. By practicing the same industry standards it recommends to partners, the organization has been honored with the following titles:   

-Great Place to Work® Employer from 2019-2025 and one of the Best Workplaces in Healthcare for 2023 by Great Place to Work Canada®
    
-The Best Leader in Diversity, Equity, and Inclusion at the 2024 Best Ottawa Business Awards    

-2024 Collaboration Catalyst by Magnet Network    

-One of Canada’s Best Places to Work by HRD Canada for 2024  
 
-5-Star Diversity, Equity and Inclusion Employer by Canadian HR Reporter since 2023     

-Employer of Choice by Canadian HR Reporter for 2025  

For more information about BioTalent Canada: biotalent.ca
For more information about the recognition program: I.D.E.A.L. Bioscience Employer Recognition Program - BioTalent Canada 

 Contact:
Stéphanie Levesque
Director – Corporate Governance & Communications
Feldan Therapeutics
slevesque@feldan.com